证券日报网1月8日讯，敷尔佳（301371）在接受调研者提问时表示，从研发项目进展上看，目前还是以 公司披露的2025年半年报信息为准。械品方面，公司2025年有一款Ⅲ类医疗器械"重组Ⅲ型人源化胶原 蛋白贴敷料"已经进入临床阶段；注射类产品，重组Ⅲ型人源化胶原蛋白冻干纤维项目临床试验已经做 完了，处于临床试验总结报告筹备阶段；重组Ⅲ型人源化胶原蛋白凝胶项目公司还处于研发阶段，争取 今年启动临床。其他品类项目的研发进展，请关注公司将于4月份披露的年度报告。 ...

证券代码：301371 证券简称：敷尔佳 哈尔滨敷尔佳科技股份有限公司 投资者关系活动记录表 编号：2026-001 投资者关系活 动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑ 现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 广发证券股份有限公司 嵇文欣、张望 易方达基金管理有限公司 黄逸群、冯业倩 时间 2026 年 1 月 8 日 10：00-11：00 地点 公司一楼花果山会议室 上市公司接待 人员姓名 张立国先生 董事长 邓百娇女士 董事、董事会秘书 吴 弘先生 证券事务代表 投资者关系活 动主要内容介 绍 Q1、请介绍一下公司双十一和双十二的上新情况，以及 明年的推新计划。 A：从 2025 年 11-12 月的上新数据看，两个月合计上新品 18 款（含旧品升级），械品和妆品各占 9 款，具体产品情况 可到公司在各大电商平台开设的官方旗舰店查询；从 2026 年 的上新计划看，械品和妆品都有，具体以实际上新情况为准。 Q2、公司在胶原蛋白化妆品和医美方面的进展有哪些？ A：从研发项目进展上看，目前还是以公司披露的 2025 年 ...

Core Viewpoint - The article highlights the success story of Yang Xia, the founder of Jinbo Biological, who transformed a small startup with 500,000 yuan into a leading biological materials company valued at over 20 billion yuan, focusing on human-derived collagen protein for the medical aesthetics industry and beyond [4][6]. Company Overview - Jinbo Biological was established in 2008 with a mission to develop recombinant human-derived collagen protein, addressing a significant gap in the market due to the high costs and limitations of natural collagen [5][6]. - The company achieved a major breakthrough in 2014 by successfully developing the first recombinant type III collagen product, leading to the establishment of the world's first production line for recombinant human-derived collagen in 2019 [6][7]. Financial Performance - Jinbo Biological went public on the Beijing Stock Exchange on July 20, 2023, with an initial stock price of 49 yuan, raising 245 million yuan. The company's market capitalization reached 12 billion yuan on its first trading day [7]. - In 2024, the company reported a revenue of 1.443 billion yuan, a sixfold increase over three years, with a net profit of 732 million yuan, reflecting a year-on-year growth of 144.3% [7][11]. Product Development - The core product, "Wei Yimei," contributed 1.254 billion yuan to the revenue, accounting for 86.89% of total sales, and is used in over 4,000 medical institutions across China [7][11]. - Jinbo Biological has received three Class III medical device certifications for its recombinant collagen injection products, establishing a strong technical barrier in the industry [8][10]. Strategic Partnerships and Investments - In 2025, Jinbo Biological announced a significant capital operation, raising 2 billion yuan through a private placement to expand production capacity and develop a collagen protein database [9]. - The company also entered into a strategic partnership with Zhong Shanshan, acquiring a 10.58% stake, which aims to leverage distribution channels for functional foods and skincare products [9][10]. Future Outlook - Jinbo Biological is expanding its applications of collagen protein beyond medical aesthetics into fields such as gynecology and orthopedics, emphasizing the material's potential as a life material [11][12]. - The company is also focusing on maintaining its competitive edge through original innovation and establishing a functional protein research institute to foster long-term technological development [11][12].